Regions of interest-based discriminant analysis of DaTSCAN SPECT and FDG-PET for the classification of dementia

Clinical Nuclear Medicine

Volumn 38, Issue 3, 2013, Pages

  Garibotto, Valentina ^a,b   Montandon, Marie Louise ^a   Viaud, Claire Tabouret ^a   Allaoua, Mohamed ^a   Assal, Frédéric ^a,b   Burkhard, Pierre R ^a,b   Ratib, Osman ^a,b   Zaidi, Habib ^a,b,c  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

brain imaging; DaTSCAN SPECT; dementia; FDG PET; quantitative analysis

Indexed keywords

DOPAMINE TRANSPORTER; FLUORODEOXYGLUCOSE; IOFLUPANE I 123;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CORTICOBASAL DEGENERATION; DEMENTIA; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; DISCRIMINANT ANALYSIS; DISEASE CLASSIFICATION; DISEASE SEVERITY; FEMALE; FRONTOTEMPORAL DEMENTIA; GLUCOSE METABOLISM; HUMAN; MALE; NEUROIMAGING; NIGRONEOSTRIATAL SYSTEM; PARKINSON DISEASE; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY; RETROSPECTIVE STUDY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

AGED; AGED, 80 AND OVER; BIOLOGICAL TRANSPORT; DEMENTIA; DISCRIMINANT ANALYSIS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RETROSPECTIVE STUDIES; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84874229548     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0b013e318279b991     Document Type: Article

References (31)

1. Brooks DJ, Pavese N. Imaging biomarkers in Parkinson's disease. Prog Neurobiol. 2011;95:614-628.
2. Varrone A, Halldin C. Molecular imaging of the dopamine transporter. J Nucl Med. 2010;51:1331-1334.
3. McKeith I, O'Brien J, Walker Z, et al. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol. 2007;6:305-313.
4. Antonini A, Benti R, De Notaris R, et al. 123I-Ioflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Neurol Sci. 2003;24:149-150.
5. Pirker W, Asenbaum S, Bencsits G, et al. [123I]beta-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration. Mov Disord. 2000;15:1158-1167.
6. Cummings JL, Henchcliffe C, Schaier S, et al. The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration. Brain. 2011;134:3146-3166.
7. Bosman T, Van Laere K, Santens P. Anatomically standardised 99mTc-ECDbrain perfusion SPET allows accurate differentiation between healthy volunteers, multiple system atrophy and idiopathic Parkinson's disease. Eur J Nucl Med Mol Imaging. 2003;30:16-24.
8. Lim SM, Katsifis A, Villemagne VL, et al. The 18F-FDG PET cingulate island sign and comparison to 123I-beta-CIT SPECT for diagnosis of dementia with Lewy bodies. J Nucl Med. 2009;50:1638-1645.
9. Foster NL, Heidebrink JL, Clark CM, et al. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. Brain. 2007; 130:2616-2635.
10. Eckert T, Barnes A, Dhawan V, et al. FDG PET in the differential diagnosis of parkinsonian disorders. Neuroimage. 2005;26:912-921.
11. Berti V, Polito C, Ramat S, et al. Brain metabolic correlates of dopaminergic degeneration in de novo idiopathic Parkinson's disease. Eur J Nucl Med Mol Imaging. 2010;37:537-544.
12. Klaffke S, Kuhn AA, Plotkin M, et al. Dopamine transporters, D2 receptors, and glucose metabolism in corticobasal degeneration. Mov Disord. 2006; 21:1724-1727.
13. Van Laere K, Casteels C, De Ceuninck L, et al. Dual-tracer dopamine transporter and perfusion SPECT in differential diagnosis of parkinsonism using template-based discriminant analysis. J Nucl Med. 2006;47:384-392.
14. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology. 1996;47:1113-1124.
15. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944.
16. Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55:181-184.
17. Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51:1546-1554.
18. Riley DE, Lang AE, Lewis A, et al. Cortical-basal ganglionic degeneration. Neurology. 1990;40:1203-1212.
19. Slomka PJ, Radau PE, Hurwitz G, et al. Automated three-dimensional quantifi cation of myocardial perfusion and brain SPECT. Comput Med Imaging Graph. 2001;25:153-164.
20. Radau PE, Slomka PJ, Julin P, et al. Evaluation of linear registration algorithms for brain SPECT and the errors due to hypoperfusion lesions. J Med Phys. 2001;28:1660-1668.
21. Koch W, Radau PE, Hamann C, et al. Clinical testing of an optimized software solution for an automated, observer-independent evaluation of dopamine transporter SPECT studies. J Nucl Med. 2005;46:1109-1118.
22. Morton RJ, Guy MJ, Clauss R, et al. Comparison of different methods of DatSCAN quantification. Nucl Med Commun. 2005;26:1139-1146.
23. Efron B. Estimating the error rate of a prediction rule: improvements on crossvalidation. J Am Stat Assoc. 1983;78:316-331.
24. Herholz K. PET studies in dementia. Ann Nucl Med. 2003;17:79-89.
25. Zhao P, Zhang B, Gao S. 18[F]-FDG PET study on the idiopathic Parkinson's disease from several parkinsonian-plus syndromes. Parkinsonism Relat Disord. 2012;18(suppl 1):S60-S62.
26. Charpentier P, Lavenu I, Defebvre L, et al. Alzheimer's disease and frontotemporal dementia are differentiated by discriminant analysis applied to (99m)Tc HmPAO SPECT data. J Neurol Neurosurg Psychiatry. 2000;69:661-663.
27. Kreisler A, Defebvre L, Lecouffe P, et al. Corticobasal degeneration and Parkinson's disease assessed by HmPaO SPECT: the utility of factorial discriminant analysis. Mov Disord. 2005;20:1431-1438.
28. Spetsieris PG, Ma Y, Dhawan V, et al. Differential diagnosis of parkinsonian syndromes using PCA-based functional imaging features. Neuroimage. 2009; 45:1241-1252.
29. Herholz K, Carter SF, Jones M. Positron emission tomography imaging in dementia. Br J Radiol. 2007;80:S160-S167.
30. Mok W, Chow TW, Zheng L, et al. Clinicopathological concordance of dementia diagnoses by community versus tertiary care clinicians. Am J Alzheimers Dis Other Demen. 2004;19:161-165.
31. Piguet O, Halliday GM, Creasey H, et al. Frontotemporal dementia and dementia with Lewy bodies in a case-control study of Alzheimer's disease. Int Psychogeriatr. 2009;21:688-695.